MRI Gadolinium‐Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs
Journal of Magnetic Resonance Imaging · 16.01.2024
DOI: 10.1002/jmri.29181 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Magnetic Resonance Imaging, online erschienen am 16.01.2024. Verfasst von Martin Bendszus und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany. Hauptthemen laut MEDLINE: Contrast Media, Magnetic Resonance Imaging, Gadolinium. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis, TEVA, Bayer.
Abstract (Originalsprache)
Gadolinium‐based contrast agents (GBCAs) are routinely used in magnetic resonance imaging (MRI). They are essential for choosing the most appropriate medical or surgical strategy for patients with serious pathologies, particularly in oncologic, inflammatory, and cardiovascular diseases. However, GBCAs have been associated with an increased risk of nephrogenic systemic fibrosis in patients with renal failure, as well as the possibility of deposition in the brain, bones, and other organs, even in patients with normal renal function. Research is underway to reduce the quantity of gadolinium injected, without compromising image quality and diagnosis. The next generation of GBCAs will enable a reduction in the gadolinium dose administered. Gadopiclenol is the first of this new generation of GBCAs, with high relaxivity, thus having the potential to reduce the gadolinium dose while maintaining good in vivo stability due to its macrocyclic structure. High‐stability and high‐relaxivity GBCAs will be one of the solutions for reducing the dose of gadolinium to be administered in clinical practice, while the development of new technologies, including optimization of MRI acquisitions, new contrast mechanisms, and artificial intelligence may help reduce the need for GBCAs. Future solutions may involve a combination of next‐generation GBCAs and image‐processing techniques to optimize diagnosis and treatment planning while minimizing exposure to gadolinium. Level of Evidence 5 Technical Efficacy Stage 3
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany.
- Department of Medical Surgical Sciences and Translational Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, Sant'Andrea University Hospital, Rome, Italy.
- Advanced Medical Imaging, Artificial Intelligence, and Imaging-Guided Therapy Research Group, Institut de Recerca Sant Pau - Centre CERCA, Barcelona, Spain.
- Diagnostic Imaging Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
- RadNet, Inc., New York, New York, USA.
- Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
ORCID-Profile: Andrea Laghi, Bachir Taouli
Förderung
- Novartis
- TEVA
- Bayer
- Grifols
- Seagen
- Deutsche Forschungsgemeinschaft
- European Union
- Hopp Foundation
Zitieren
APA
Bendszus, M., Laghi, A., Munuera, J., Tanenbaum, L. N., Taouli, B., & Thoeny, H. C. (2024). MRI Gadolinium‐Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs. Journal of Magnetic Resonance Imaging. https://doi.org/10.1002/jmri.29181
Vancouver
Bendszus M, Laghi A, Munuera J, Tanenbaum LN, Taouli B, Thoeny HC. MRI Gadolinium‐Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs. Journal of Magnetic Resonance Imaging. 2024. doi:10.1002/jmri.29181
BibTeX
@article{Bendszus2024,
author = {Bendszus, Martin and Laghi, Andrea and Munuera, Josep and Tanenbaum, Lawrence N and Taouli, Bachir and Thoeny, Harriet C},
title = {MRI Gadolinium‐Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs},
journal = {Journal of Magnetic Resonance Imaging},
year = {2024},
doi = {10.1002/jmri.29181}
}
EUVIMED